Literature DB >> 16943408

Risks and benefits of celecoxib to prevent recurrent adenomas.

Bruce M Psaty, John D Potter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943408     DOI: 10.1056/NEJMe068158

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  30 in total

Review 1.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  DFMO: targeted risk reduction therapy for colorectal neoplasia.

Authors:  Christina M Laukaitis; Eugene W Gerner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 3.  A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia.

Authors:  J T Cross; E M Poole; C M Ulrich
Journal:  Pharmacogenomics J       Date:  2008-01-15       Impact factor: 3.550

Review 4.  Molecular targets for cancer chemoprevention.

Authors:  William N William; John V Heymach; Edward S Kim; Scott M Lippman
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

Review 5.  Optical molecular imaging and its emerging role in colorectal cancer.

Authors:  Rahul A Sheth; Umar Mahmood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-01       Impact factor: 4.052

6.  Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.

Authors:  Bin Su; Michael V Darby; Robert W Brueggemeier
Journal:  J Comb Chem       Date:  2008-04-02

Review 7.  RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

Authors:  Antonio Strillacci; Cristiana Griffoni; Maria Chiara Valerii; Giorgia Lazzarini; Vittorio Tomasi; Enzo Spisni
Journal:  J Biomed Biotechnol       Date:  2010-06-13

8.  Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.

Authors:  Zhihong Yang; Hang Xiao; Huanyu Jin; Phillip T Koo; Dorothea J Tsang; Chung S Yang
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

9.  Lung tumor promotion by curcumin.

Authors:  Stephanie T Dance-Barnes; Nancy D Kock; Joseph E Moore; Elaine Y Lin; Libyadda J Mosley; Ralph B D'Agostino; Thomas P McCoy; Alan J Townsend; Mark Steven Miller
Journal:  Carcinogenesis       Date:  2009-04-09       Impact factor: 4.944

10.  Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.

Authors:  Guo-Shuang Feng; Jun-Ling Ma; Benjamin C Y Wong; Lian Zhang; Wei-Dong Liu; Kai-Feng Pan; Lin Shen; Xiao-Dong Zhang; Jie Li; Harry Hx Xia; Ji-You Li; Shiu Kum Lam; Wei-Cheng You
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.